

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034837 A3

(51) **International Patent Classification:**
A61K 31/713 (2006.01) *C12P 19/34* (2006.01)
(21) **International Application Number:**
PCT/US2022/075715
(22) **International Filing Date:**
31 August 2022 (31.08.2022)
(25) **Filing Language:** English
(26) **Publication Language:** English
(30) **Priority Data:**
63/239,271 31 August 2021 (31.08.2021) US
63/341,848 13 May 2022 (13.05.2022) US

(71) **Applicant:** **ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, Massachusetts 02142 (US).

(72) **Inventors:** **ZUBER, Jeffrey**; c/o Alnylam Pharmaceu-
ticals, Inc., 675 West Kendall Street, Henri A. Ter-
meer Square, Cambridge, Massachusetts 02142 (US).
MCININCH, James D.; c/o Alnylam Pharmaceuticals,
Inc., 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, Massachusetts 02142 (US). **SCHLEGEL,**
Mark K.; c/o Alnylam Pharmaceuticals, Inc., 675 West
Kendall Street, Henri A. Termeer Square, Cambridge,
Massachusetts 02142 (US). **CASTORENO, Adam**; c/o Al-
nylam Pharmaceuticals, Inc., 675 West Kendall Street, Hen-
ri A. Termeer Square, Cambridge, Massachusetts 02142
(US). **BONDURANT, Lucas**; c/o Alnylam Pharmaceu-
ticals, Inc., 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, Massachusetts 02142 (US). **OZA,**
Dhaval; c/o Alnylam Pharmaceuticals, Inc., 675 West
Kendall Street, Henri A. Termeer Square, Cambridge,
Massachusetts 02142 (US).

(74) **Agent:** **MEIGS, Julie Broadus et al.**; Womble Bond
Dickinson (US) LLP, P.O. Box 570489, Atlanta, Georgia
30357-0037 (US).

(81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) **Date of publication of the international search report:**
06 April 2023 (06.04.2023)

(54) **Title:** CELL DEATH-INDUCING DFFA-LIKE EFFECTOR B (CIDEB) IRNA COMPOSITIONS AND METHODS OF USE
THEREOF

(57) **Abstract:** The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CIDEB gene, as well
as methods of inhibiting expression of CIDEB, and methods of treating subjects that would benefit from reduction in expression of
CIDEB, such as subjects having a CIDEB-associated disease, disorder, or condition, using such dsRNA compositions.

WO 2023/034837 A3